🇺🇸 FDA
Pipeline program

Dexmedetomidine

DEX-THYROID-RCT-2025

Approved small_molecule active

Quick answer

Dexmedetomidine for Thyroid Diseases is a Approved program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Thyroid Diseases
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials